868049-68-7

Usage

Uses

Used in Pharmaceutical Research:
1-(2,4-difluorophenyl)-2-methylpropan-2-ol is used as a reagent for its potential in creating diverse chemical structures and properties, which can be beneficial in the development of new drugs and pharmaceuticals.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(2,4-difluorophenyl)-2-methylpropan-2-ol is used as a reagent due to its unique structure, which allows for various chemical reactions and the formation of different compounds.
Used in Material Science:
1-(2,4-difluorophenyl)-2-methylpropan-2-ol may also find applications in material science, where its unique properties can be utilized to develop new materials with specific characteristics.

Upstream product

• 81228-09-3 2,4-difluorophenylacetic acid 
• 95299-17-5 methyl 2-(2,4-difluorophenyl)acetate 
• 75-16-1 methylmagnesium bromide 
• 67-64-1 acetone 
• 546122-71-8 2,4-difluorobenzylmagnesium bromide 

Relevant academic research and scientific papers

Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity

IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases. As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders. We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4. Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models. Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors. We identified potent molecule 19 that achieves robust in vivo inhibition of cytokines relevant to human disease.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (0), Formula (I), and Formula (II) and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Novel medicaments for the treatment of respiratory diseases

The present invention relates to the use of the compounds of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claims and in the specification, for preparing a pharmaceutical composition

Aerosol formulation for the inhalation of beta-agonists

The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula 1 wherein the groups R1, R2, R3 and X? may have the meanings given in the claims a

Novel medicament combinations for the treatment of respiratory diseases

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claim